New Zealand Naltrexone Funding: June 2026 PHARMAC Check
Naltraccord 50 mg is fully subsidised under SA1408, while pharmacy charges and GP fees remain separate.
Key takeaways
- Funded product: Naltraccord, naltrexone 50 mg tablets.
- Funding condition: Special Authority SA1408.
- Standard pharmacy charge: $5 per approved medicine, with specified exemptions.
- GP consultation fees vary by practice and eligibility.
- Funding evidence does not establish extended-release injection supply.
What SA1408 changes
Special Authority is PHARMAC’s mechanism for restricting subsidy to defined criteria. The prescriber must check the current Schedule and submit the required application. The rules are not means-tested in the same way as a welfare benefit, but clinical and prescriber criteria still matter.
Because criteria can change, this post does not paraphrase them as a permanent checklist. The live Schedule is the source of truth.
Funding, dispensing, and clinical care are separate
| Part of the pathway | What the public evidence establishes |
|---|---|
| Medicine subsidy | Naltraccord 50 mg is fully subsidised when SA1408 is met |
| Pharmacy charge | Standard $5 charge unless exempt |
| GP visit | General practices set their own fees |
| Addiction-service care | Service availability and referral routes vary locally |
| Injectable naltrexone | Routine funded availability was not established by the Naltraccord listing |
Health New Zealand lists pharmacy-charge exemptions including people aged 13 or under, Community Services Card holders and their dependants, and people aged 65 or over. Check the current page because eligibility rules can change.
What to verify before treatment
- Whether the current SA1408 criteria are met.
- Who will submit and renew the authority.
- Which pharmacy can supply Naltraccord.
- Whether the $5 charge or an exemption applies.
- The GP or specialist consultation fee.